Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

169.91 -2.19 (-1.27%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

56 57 Next >

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

February 27, 2023

From Biogen Inc.

Via GlobeNewswire

Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit ↗

February 27, 2023

The FDA is set to review the company's neurological drug by Tuesday.

Via Investor's Business Daily

Why Reata Pharmaceuticals Shares Are Falling Monday? ↗

February 27, 2023

According to various reports, the FDA's neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately.

Via Benzinga

Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca ↗

February 25, 2023

Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...

Via Talk Markets

Biogen (BIIB) Q4 2022 Earnings Call Transcript ↗

February 15, 2023

BIIB earnings call for the period ending December 31, 2022.

Via The Motley Fool

Why Biogen Stock Is Falling Today ↗

February 15, 2023

Via Benzinga

Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales ↗

February 15, 2023

The company expects "modest" Leqembi sales, but there's a caveat.

Via Investor's Business Daily

3 More Mid-Cap Biotechs The Street Sees Doubling

February 22, 2023

According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.

Via MarketBeat

Analyst Initiates Coverage of GE Healthcare, Says' Path To Greatness Well-Paved' ↗

February 17, 2023

Via Benzinga

Biogen Beats Q4 Earnings & Sales Estimates, Stock Up ↗

February 15, 2023

Biogen reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05.

Via Talk Markets

Cisco, Analog Devices And 3 Stocks To Watch Heading Into Wednesday ↗

February 15, 2023

With US futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

US Stocks Settle Mixed; Investor Optimism Improves ↗

February 15, 2023

The CNN Money Fear and Greed index showed an improvement in the overall sentiment among US investors.

Via Benzinga

2 Top Biotech Stocks Defying the Bear Market ↗

February 08, 2023

These stocks soared in the double digits last year.

Via The Motley Fool

Is Biogen Stock a Buy Now? ↗

January 26, 2023

Its new drug might succeed where the company faltered in 2021.

Via The Motley Fool

Where Biogen Stands With Analysts ↗

January 24, 2023

Via Benzinga

Investors Are Awaiting The Name Of The New BoJ Governor ↗

February 13, 2023

This week, the Japanese government will officially elect a new Governor of the Bank of Japan to replace Haruhiko Kuroda, whose decade at the Central Bank will end in April.

Via Talk Markets

Q4 Reporting Season Pushes Past Halfway Mark: Coca-Cola, Cisco Systems, Palantir, Roku Lead Earnings This Week ↗

February 12, 2023

The stock market pulled back in the week ended Feb. 10, dragged by some disappointing earnings and revised December inflation data.

Via Benzinga

Why Anavex Life Sciences Stock Bolted Higher in January ↗

February 08, 2023

The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.

Via The Motley Fool

Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive' ↗

February 06, 2023

Via Benzinga

Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

February 06, 2023

From Sage Therapeutics, Inc.

Via Business Wire

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

February 06, 2023

From Biogen Inc.

Via GlobeNewswire

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric ↗

February 02, 2023

The company that remains still has a large pipeline of non-migraine assets.

Via Investor's Business Daily

The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023 ↗

February 01, 2023

For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy.

Via InvestorPlace

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

Cassava Sciences Stock Undervalued with Its $124 Price Target?

January 30, 2023

Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a

Via MarketBeat

Lecanemab Receives Priority Review Status in Japan

January 29, 2023

From Biogen Inc.

Via GlobeNewswire

Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

January 26, 2023

From Biogen Inc.

Via GlobeNewswire

Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback? ↗

January 25, 2023

Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.

Via The Motley Fool

In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug ↗

January 20, 2023

The company will need to complete its confirmatory study before asking for approval.

Via Investor's Business Daily

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.